OPKO4K is a blood test which assesses the risk of aggressive PC by combining four prostate-specific biomarkers (Total PSA, Free PSA, Intact PSA, and human Kallikrein 2 [hK2]) with important clinical factors (age, prior biopsy status, and optional DRE). Here, KLK3 is linked to pachyonychia congenita.